---
title: "Descartes-08 in Generalized myasthenia gravis: Effect on quality measures"
description: "Formulary evidence on Descartes-08 in Generalized myasthenia gravis: Effect on quality measures. Topics: AAN quality measure: immunosuppressive therapy for myasthenic crisis. 1 evidence topic quoted from 1 source."
canonical: "https://www.evicenter.com/drugs/descartes-08--generalized-myasthenia-gravis/product-information-and-disease-description/effect-on-quality-measures"
published: "2026-11-19T12:09:07-05:00"
modified: "2026-11-19T12:09:07-05:00"
---

# Descartes-08 in Generalized myasthenia gravis: Effect on quality measures

<a id="heading-2.1.2.13"></a>

## 2.1.2.13 Effect of Descartes-08 on Quality Measures

<a id="topic-2.1.2.13-1"></a>

### AAN quality measure: immunosuppressive therapy for myasthenic crisis

> “Measure purpose: Rapidly initiate treatment for myasthenic crisis and thereby wean from mechanical ventilation, reduce likelihood of tracheostomy, and increase functional independence”
> “The numerator: Patients with myasthenic crisis that are given immunosuppressive therapies (Plasmapheresis (PE) or intravenous immunoglobulin (IVIG))”
> “The denominator: Patients admitted to inpatient facility with a diagnosis of myasthenic crisis”

Source: [American Academy of Neurology myasthenic crisis quality measure](https://www.aan.com/practice/immunosuppressive-therapy-myasthenic-crisis-quality-measure)

<a id="topic-2.1.2.13-2"></a>

### Product-specific effect on quality measures

No evidence found.

## Related pages
- [Descartes-08: Generalized myasthenia gravis](https://www.evicenter.com/drugs/descartes-08--generalized-myasthenia-gravis) · [Markdown](https://www.evicenter.com/drugs/descartes-08--generalized-myasthenia-gravis.md)
- [Descartes-08 in Generalized myasthenia gravis: Terms and abbreviations](https://www.evicenter.com/drugs/descartes-08--generalized-myasthenia-gravis/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/descartes-08--generalized-myasthenia-gravis/terms-and-abbreviations.md)
- [Descartes-08: Generalized myasthenia gravis](https://www.evicenter.com/drugs/descartes-08--generalized-myasthenia-gravis/executive-summary) · [Markdown](https://www.evicenter.com/drugs/descartes-08--generalized-myasthenia-gravis/executive-summary.md)
- [Descartes-08 in Generalized myasthenia gravis: Product information and disease description](https://www.evicenter.com/drugs/descartes-08--generalized-myasthenia-gravis/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/descartes-08--generalized-myasthenia-gravis/product-information-and-disease-description.md)
- [Descartes-08 in Generalized myasthenia gravis: Clinical evidence](https://www.evicenter.com/drugs/descartes-08--generalized-myasthenia-gravis/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/descartes-08--generalized-myasthenia-gravis/clinical-evidence.md)
- [Descartes-08 in Generalized myasthenia gravis: Economic information and modeling report](https://www.evicenter.com/drugs/descartes-08--generalized-myasthenia-gravis/economics) · [Markdown](https://www.evicenter.com/drugs/descartes-08--generalized-myasthenia-gravis/economics.md)
- [Descartes-08 in Generalized myasthenia gravis: References](https://www.evicenter.com/drugs/descartes-08--generalized-myasthenia-gravis/references) · [Markdown](https://www.evicenter.com/drugs/descartes-08--generalized-myasthenia-gravis/references.md)
